FINWIRES · TerminalLIVE
FINWIRES

CIBC Raises Its Primaris REIT Price Target By C$2, Reiterates its Outperformer Rating

By

-- CIBC Capital Markets reiterated its outperformer rating on the shares of Primaris Real Estate Investment Trust (PMZ-UN.TO) while raising its price target to C$22.00 from C$20.00 on Thursday, following PMZ's first quarter results on Wednesday.

PMZ reported Q1 FFO/unit of $0.425 (-3.2% Y/Y), broadly in line with consensus, noted CIBC.

"Our 2027 FFO/unit estimate rises by near 2%, as we better reflect the improved leasing cadence on the ground," said CIBC, adding it $22 price target is based on an 11 times 2027 estimated FFO/unit multiple (10.2 times previously), translating to a 5% discount to the bank's revised one-year-out NAV (9% previously), "reflective of its risk, growth prospects, and leverage versus peers."

CIBC also reiterated its belief that PMZ unitholders will benefit from occupancy improvements and rent growth over the long term. Tenant relationships for mall operators matter given the reach of their typically national tenant base, CIBC said. Controlling increasingly more productive assets through acquisition and organic growth will increase PMZ's importance to these national tenants, the bank added.

"PMZ's ability to fund its capex and distribution from its own rents and low balance sheet leverage drive a lower financial risk profile that offsets the risk of owning a higher-risk asset class in enclosed malls," added CIBC. Trading at an implied cap rate of near 8.7% on achievable forecasts, CIBC believes investors are being well compensated for the operating risks involved with owning PMZ units (e.g., anchor tenant transitions) versus the balance of the large-cap Canadian retail REIT universe (trading at estimated implied cap rates of 5.8%-7.1%)."

CIBC noted on the call that Primaris will provide a detailed update on its HBC progress in the next 60 days, once it has a significant number of fully executed leases in place, and also that CRU leasing momentum "accelerated meaningfully" in Q1, with management highlighting record new deal volumes and pricing.

Price: $19.01, Change: $+0.14, Percent Change: +0.74%

Related Articles

Australia

Novartis Gains Canada Nod for Fabhalta in Rare Kidney Disease

Novartis (NVS) said Health Canada has approved Fabhalta for the treatment of adults with complement 3 glomerulopathy (C3G), to reduce proteinuria.C3G is a rare, long-term kidney disease caused by an overactive immune pathway. This leads to a buildup of protein in the kidneys, causing inflammation, damage and, over time, loss of kidney function.The approval was backed by Phase III data showing a statistically significant reduction in proteinuria at six months, with sustained benefits through one year.Fabhalta (iptacopan) is an oral drug that blocks a key part of the immune system (Factor B), helping reduce the harmful activity that drives C3G and protects the kidneys.Price: $146.84, Change: $-1.01, Percent Change: -0.68%

$NVS
Research

Research Alert: CFRA Maintains Hold Rating On Shares Of Commvault Systems Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our target price to $106, from $101, on a forward P/E of 21x our FY 27 EPS estimate of $5.05, below its three-year average. We increase our FY 27 EPS projection to $5.05 from $4.80, and start our FY 28 EPS forecast at $5.90. CVLT reported solid Q4 results, above consensus views, with total revenue rising 13% Y/Y to $312M, fueled by subscription revenue growth of 20% to $208M and strong SaaS revenue contribution of $93M (+43% Y/Y). SaaS ARR rose 42% to $400M, while subscription ARR hit $989M, up 27% Y/Y, with net new ARR of $53M marking the strongest quarterly performance of FY26. Results reflect momentum in the business as CVLT benefits from data security challenges from AI use. We anticipate long-term tailwinds, but note greater macro and demand uncertainty in FY 27. We highlight impressive FCF generation (record $132M) and continued margin expansion expected in the new fiscal year.

$CVLT
Commodities

US Soybean Crush Rose in March, Stocks Tightened, USDA Says

The US Department of Agriculture on Friday reported that soybean crush for March rose above February and year-ago totals, but stocks dropped.In its monthly Oilseed Crushings, Production, Consumption and Stocks Report, the USDA pegged soybeans crushed for crude oil at 6.82 million metric tons, or 227 mb, in March 2026, compared with 6.43 million mt, or 214 mb, in February 2026, and 6.20 million mt, or 207 mb, in March 2025.The amount of crude oil produced from crushed soybeans was 2.64 billion pounds, up 6% from February 2026 and up 7% from March 2025.Production of soybean oil, once refined, totaled 2 billion pounds in March 2026, up 14% from February 2026 and 7% from March 2025.Iowa facilities crushed a total of 1.5 million mt, followed by facilities in the North and Eastern US, totaling 1.3 million mt.Soybean-based crude oil stocks, as of March 31, 2026, totaled 2 billion pounds, slightly below 2.1 billion in February.Corn oil crushed to produce crude oil totaled 139 million pounds in March, above 132.7 million pounds in February.